FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
FDA chief named in payments controversy; fake vaccine scandal impacts Indonesian children
This
week Phispers brings you scandals such as that of fake vaccines in Indonesia,
studies and analy